Wang Xu, Ling Li, Su Hong, Cheng Jian, Jin Liu
Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, 81 Meishan Road, Hefei 230032, Anhui Province, China E-mail :
Asian Pac J Cancer Prev. 2014;15(11):4467-74. doi: 10.7314/apjcp.2014.15.11.4467.
We aimed to comprehensively review the evidence for using sputum DNA to detect non-small cell lung cancer (NSCLC).
We searched PubMed, Science Direct, Web of Science, Chinese Biological Medicine (CBM), Chinese National Knowledge Infrastructure (CNKI), Wanfang, Vip Databases and Google Scholar from 2003 to 2013. The meta-analysis was carried out using a random-effect model with sensitivity, specificity, diagnostic odd ratios (DOR), summary receiver operating characteristic curves (ROC curves), area under the curve (AUC), and 95% confidence intervals (CI) as effect measurements.
There were twenty-two studies meeting the inclusion criteria for the meta-analysis. Combined sensitivity and specificity were 0.62 (95%CI: 0.59-0.65) and 0.73 (95%CI: 0.70-0.75), respectively. The DOR was 10.3 (95%CI: 5.88-18.1) and the AUC was 0.78.
The overall accuracy of the test was currently not strong enough for the detection of NSCLC for clinical application. Discovery and evaluation of additional biomarkers with improved sensitivity and specificity from studies rated high quality deserve further attention.
我们旨在全面回顾使用痰液DNA检测非小细胞肺癌(NSCLC)的证据。
我们检索了2003年至2013年期间的PubMed、Science Direct、Web of Science、中国生物医学文献数据库(CBM)、中国知网(CNKI)、万方数据库、维普数据库和谷歌学术。采用随机效应模型进行荟萃分析,以灵敏度、特异度、诊断比值比(DOR)、汇总受试者工作特征曲线(ROC曲线)、曲线下面积(AUC)和95%置信区间(CI)作为效应测量指标。
有22项研究符合荟萃分析的纳入标准。合并灵敏度和特异度分别为0.62(95%CI:0.59 - 0.65)和0.73(95%CI:0.70 - 0.75)。诊断比值比为10.3(95%CI:5.88 - 18.1),曲线下面积为0.78。
目前该检测方法的总体准确性对于临床应用检测非小细胞肺癌来说还不够强。从高质量研究中发现和评估具有更高灵敏度和特异度的其他生物标志物值得进一步关注。